Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor, Zoliflodacin.

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP.

J Clin Microbiol. 2019 Jul 17. pii: JCM.00567-19. doi: 10.1128/JCM.00567-19. [Epub ahead of print]

PMID:
31315953
2.

In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected During an International Surveillance Program (2017).

Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M.

Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00840-19. doi: 10.1128/AAC.00840-19. [Epub ahead of print]

PMID:
31182527
3.

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-lactamase Inhibitor Enmetazobactam.

Belley A, Huband MD, Fedler KA, Watters AA, Flamm RK, Shapiro S, Knechtle P.

J Clin Microbiol. 2019 Jun 5. pii: JCM.00607-19. doi: 10.1128/JCM.00607-19. [Epub ahead of print]

PMID:
31167844
4.

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016.

Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S63-S68. doi: 10.1093/ofid/ofy343. eCollection 2019 Mar.

5.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Huband MD, Pfaller MA, Shortridge D, Flamm RK.

J Glob Antimicrob Resist. 2019 Feb 27. pii: S2213-7165(19)30057-8. doi: 10.1016/j.jgar.2019.02.017. [Epub ahead of print]

PMID:
30825698
6.

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02262-18. doi: 10.1128/AAC.02262-18. Print 2019 Mar.

PMID:
30617092
7.

Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.

Sader HS, Streit JM, Carvalhaes CG, Huband MD, Pfaller MA.

J Glob Antimicrob Resist. 2019 Jun;17:103-108. doi: 10.1016/j.jgar.2018.11.013. Epub 2018 Nov 17.

PMID:
30458298
8.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Bradford PA, Huband MD, Stone GG.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00223-18. doi: 10.1128/AAC.00223-18. Print 2018 Jul.

9.

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):179-183. doi: 10.1016/j.diagmicrobio.2018.01.019. Epub 2018 Feb 24.

PMID:
29571839
10.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

11.

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M.

Int J Antimicrob Agents. 2018 Aug;52(2):144-150. doi: 10.1016/j.ijantimicag.2018.02.021. Epub 2018 Mar 3.

PMID:
29510189
12.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
13.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Pfaller MA, Huband MD, Shortridge D, Flamm RK.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

14.

Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.

Munson E, Huband MD, Castanheira M, Fedler KA, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):324-328. doi: 10.1016/j.diagmicrobio.2017.11.019. Epub 2017 Dec 5.

PMID:
29276104
15.
16.

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):143-147. doi: 10.1016/j.diagmicrobio.2017.10.010. Epub 2017 Oct 19.

PMID:
29157954
17.
18.
19.

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R, Zook C.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3353-3358. doi: 10.1016/j.bmcl.2017.06.009. Epub 2017 Jun 3.

PMID:
28610977
20.

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.

Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA, Flamm RK.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):198-200. doi: 10.1016/j.diagmicrobio.2017.03.011. Epub 2017 Mar 23.

PMID:
28410852
21.

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations.

McLeod SM, Patey SA, Huband MD, Nichols WW.

Int J Antimicrob Agents. 2017 Apr;49(4):437-442. doi: 10.1016/j.ijantimicag.2016.12.011. Epub 2017 Feb 24.

PMID:
28242258
22.

Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.

Pfaller MA, Huband MD, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00018-17. doi: 10.1128/AAC.00018-17. Print 2017 May.

23.

Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Sader HS, Huband MD, Castanheira M, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02252-16. doi: 10.1128/AAC.02252-16. Print 2017 Mar.

24.

Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.

Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02411-16. doi: 10.1128/AAC.02411-16. Print 2017 Mar.

25.

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914.

Giacobbe RA, Huband MD, deJonge BL, Bradford PA.

Diagn Microbiol Infect Dis. 2017 Feb;87(2):139-142. doi: 10.1016/j.diagmicrobio.2016.03.007. Epub 2016 Mar 8.

PMID:
27856046
26.

In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Flamm RK, Rhomberg PR, Huband MD, Farrell DJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5. doi: 10.1128/AAC.00941-16. Print 2016 Oct.

27.

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).

Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2016 Jun;47(6):495-9. doi: 10.1016/j.ijantimicag.2016.04.009. Epub 2016 May 12.

PMID:
27211209
28.

Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.

Sader HS, Castanheira M, Flamm RK, Huband MD, Jones RN.

Surg Infect (Larchmt). 2016 Aug;17(4):473-8. doi: 10.1089/sur.2016.036. Epub 2016 Apr 22.

PMID:
27104633
29.

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.

Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader HS.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.

30.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

31.

In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.

Waites KB, Crabb DM, Duffy LB, Huband MD.

Antimicrob Agents Chemother. 2015;59(6):3627-9. doi: 10.1128/AAC.04945-14. Epub 2015 Mar 30.

32.

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.

33.

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP.

Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.

34.

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP.

Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.

35.

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.

Dallow J, Otterson LG, Huband MD, Krause KM, Nichols WW.

Int J Antimicrob Agents. 2014 Dec;44(6):552-6. doi: 10.1016/j.ijantimicag.2014.07.023. Epub 2014 Sep 16.

PMID:
25293578
36.

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.

Kohlhoff SA, Huband MD, Hammerschlag MR.

Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6.

37.

Pyridone-conjugated monobactam antibiotics with gram-negative activity.

Brown MF, Mitton-Fry MJ, Arcari JT, Barham R, Casavant J, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Lall MS, Lemmon MM, Li C, Lin J, McCurdy SP, McElroy E, McPherson C, Marr ES, Mueller JP, Mullins L, Nikitenko AA, Noe MC, Penzien J, Plummer MS, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Tomaras A, Young JA, Zaniewski RP.

J Med Chem. 2013 Jul 11;56(13):5541-52. doi: 10.1021/jm400560z. Epub 2013 Jun 27.

PMID:
23755848
38.

Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.

Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM Jr, Nicolau DP, Nguyen TT, Noe MC, O'Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM.

J Med Chem. 2013 Jun 27;56(12):5079-93. doi: 10.1021/jm400416u. Epub 2013 Jun 18.

PMID:
23735048
39.

Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio.

Mendes RE, Deshpande LM, Bonilla HF, Schwarz S, Huband MD, Jones RN, Quinn JP.

Antimicrob Agents Chemother. 2013 Jul;57(7):2923-8. doi: 10.1128/AAC.00071-13. Epub 2013 Apr 9.

40.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C.

Bioorg Med Chem Lett. 2013 May 15;23(10):2955-61. doi: 10.1016/j.bmcl.2013.03.047. Epub 2013 Mar 21.

PMID:
23566517
41.

Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates.

Magee TV, Han S, McCurdy SP, Nguyen TT, Granskog K, Marr ES, Maguire BA, Huband MD, Chen JM, Subashi TA, Shanmugasundaram V.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1727-31. doi: 10.1016/j.bmcl.2013.01.067. Epub 2013 Jan 26.

PMID:
23414806
42.

Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.

Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5989-94. doi: 10.1016/j.bmcl.2012.07.005. Epub 2012 Jul 20. Erratum in: Bioorg Med Chem Lett. 2015 Sep 15;25(18):4029.

PMID:
22892121
43.

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.

Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD.

ACS Med Chem Lett. 2011 Mar 2;2(5):385-90. doi: 10.1021/ml200012f. eCollection 2011 May 12.

44.

Successful eradication of a monoclonal strain of Klebsiella pneumoniae during a K. pneumoniae carbapenemase-producing K. pneumoniae outbreak in a surgical intensive care unit in Miami, Florida.

Munoz-Price LS, De La Cuesta C, Adams S, Wyckoff M, Cleary T, McCurdy SP, Huband MD, Lemmon MM, Lescoe M, Dibhajj FB, Hayden MK, Lolans K, Quinn JP.

Infect Control Hosp Epidemiol. 2010 Oct;31(10):1074-7. doi: 10.1086/656243.

PMID:
20738186
45.

Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain.

Bonilla H, Huband MD, Seidel J, Schmidt H, Lescoe M, McCurdy SP, Lemmon MM, Brennan LA, Tait-Kamradt A, Puzniak L, Quinn JP.

Clin Infect Dis. 2010 Oct 1;51(7):796-800. doi: 10.1086/656281.

PMID:
20726771
46.

Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization.

Mulanovich VE, Huband MD, McCurdy SP, Lemmon MM, Lescoe M, Jiang Y, Rolston KV, LaSala PR.

J Antimicrob Chemother. 2010 Sep;65(9):2001-4. doi: 10.1093/jac/dkq238. Epub 2010 Jun 25.

PMID:
20581120
47.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.

J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.

PMID:
19775168
48.

5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.

Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H, Gage JW, Lockard M, Rauckhorst MR, Owen RM, Lall MS, Tomilo M, Chen H, McCurdy SP, Barbachyn MR.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5302-6. doi: 10.1016/j.bmcl.2009.07.141. Epub 2009 Aug 3.

PMID:
19683922
49.

Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches.

Mochalkin I, Miller JR, Narasimhan L, Thanabal V, Erdman P, Cox PB, Prasad JV, Lightle S, Huband MD, Stover CK.

ACS Chem Biol. 2009 Jun 19;4(6):473-83. doi: 10.1021/cb9000102.

PMID:
19413326
50.

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore.

Miller JR, Dunham S, Mochalkin I, Banotai C, Bowman M, Buist S, Dunkle B, Hanna D, Harwood HJ, Huband MD, Karnovsky A, Kuhn M, Limberakis C, Liu JY, Mehrens S, Mueller WT, Narasimhan L, Ogden A, Ohren J, Prasad JV, Shelly JA, Skerlos L, Sulavik M, Thomas VH, VanderRoest S, Wang L, Wang Z, Whitton A, Zhu T, Stover CK.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1737-42. doi: 10.1073/pnas.0811275106. Epub 2009 Jan 22.

Supplemental Content

Loading ...
Support Center